GURUFOCUS.COM » STOCK LIST » USA » NAS » HilleVax Inc (NAS:HLVX) » Definitions » Debt-to-EBITDA
Switch to:

HilleVax Debt-to-EBITDA

: -1.59 (As of Dec. 2021)
View and export this data going back to 2022. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

HilleVax's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2021 was $158.31 Mil. HilleVax's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2021 was $0.15 Mil. HilleVax's annualized EBITDA for the quarter that ended in Dec. 2021 was $-99.56 Mil. HilleVax's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2021 was -1.59.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for HilleVax's Debt-to-EBITDA or its related term are showing as below:

HLVX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.59   Med: -1.53   Max: -1.46
Current: -1.59

During the past 2 years, the highest Debt-to-EBITDA Ratio of HilleVax was -1.46. The lowest was -1.59. And the median was -1.53.

HLVX's Debt-to-EBITDA is ranked worse than
100% of 301 companies
in the Biotechnology industry
Industry Median: 0.91 vs HLVX: -1.59

HilleVax Debt-to-EBITDA Historical Data

The historical data trend for HilleVax's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HilleVax Annual Data
Trend Dec20 Dec21
Debt-to-EBITDA
-1.46 -1.59

HilleVax Semi-Annual Data
Dec20 Dec21
Debt-to-EBITDA -1.46 -1.59

Competitive Comparison

For the Biotechnology subindustry, HilleVax's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

HilleVax Debt-to-EBITDA Distribution

For the Biotechnology industry and Healthcare sector, HilleVax's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where HilleVax's Debt-to-EBITDA falls into.



HilleVax Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

HilleVax's Debt-to-EBITDA for the fiscal year that ended in Dec. 2021 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(158.308 + 0.153) / -99.561
=-1.59

HilleVax's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2021 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(158.308 + 0.153) / -99.561
=-1.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is one times the quarterly (Dec. 2021) EBITDA data.


HilleVax  (NAS:HLVX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


HilleVax Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of HilleVax's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


HilleVax Business Description

HilleVax logo
Traded in Other Exchanges
N/A
Address
Website
Executives
Fhmls X, L.l.c. 10 percent owner 601 UNION STREET, SUITE 3200 TWO UNION SQUARE SEATTLE WA 98101
Dubin Gary director C/O HILLEVAX, INC. 75 STATE STREET, SUITE 100 - #9995 BOSTON MA 02109
Borkowski Astrid officer: Chief Medical Officer C/O HILLEVAX, INC. 75 STATE STREET, SUITE 100 - #9995 BOSTON MA 02109
Sepulveda Jaime director C/O HILLEVAX INC. 75 STATE STREET 100 - #9995 BOSTON MA 02109
Takeda Vaccines, Inc. 10 percent owner 75 SIDNEY STREET CAMBRIDGE MA 02139
Chu Shelley director ONE WINTHROP SQUARE SUITE 400 BOSTON MA 02110
Silbermann Susan Michele director C/O LIANBIO 103 CARNEGIE CENTER DRIVE, SUITE 215 PRINCETON NJ 08540
Fhmls X, L.p. 10 percent owner 601 UNION STREET, SUITE 3200 TWO UNION SQUARE SEATTLE WA 98101
Frazier Life Sciences X, L.p. 10 percent owner 601 UNION STREET, SUITE 3200 TWO UNION SQUARE SEATTLE WA 98101
Gerberding Julie L. director 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033
Kohli Aditya director, officer: Chief Operating Officer C/O PHATHOM PHARMACEUTICALS, INC. 2150 E. LAKE COOK ROAD, SUITE 800 BUFFALO GROVE IL 60089
Socks David A officer: CFO & Chief Business Officer C/O CADENCE PHARMACEUTICALS, INC. 12481 HIGH BLUFF DRIVE, SUITE 200 SAN DIEGO CA 92130
Takeda Pharmaceutical Co Ltd 10 percent owner 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU TOKYO M0 103-8668
Hershberg Robert director, officer: President and CEO 3005 FIRST AVENUE SEATTLE WA 98121
Topper James N 10 percent owner 550 HAMILTON AVENUE, SUITE 100 PALO ALTO CA 94301
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)